Using the CDD Vault for MM4TB
Download as PPTX, PDF1 like976 views
The document discusses the use of the Collaborative Drug Discovery (CDD) vault in tuberculosis (TB) drug development, highlighting the importance of collaboration among academia and industry to share data and resources. It mentions key collaborations, including a project involving major pharmaceutical companies and academic institutions, aimed at enhancing TB drug discovery through computational data mining and targeted compound library sharing. Over a decade of efforts have established a secure framework for collaboration that accelerates the development of new therapies.
Using the CDD Vault for MM4TB
- 1. Using the CDD Vault for MM4TB Sean Ekins PhD, DSc. CSO, Collaborative Drug Discovery, Inc Burlingame, CA
- 2. The Exploitation pathway… Torbjörn Ingemansson European Commission Sean Ekins Collaborative Drug Discovery, Inc. Claire Skentelbery European Biotechnology Network Bonny Harbinger National Institutes of Health
- 3. “by provisioning the right amount of storage and compute resources, cost can be significantly reduced with no significant impact on application performance”
- 4. CDD- a decade of drug discovery collaborations2004 - present SaaS Easy to use Used by Academia Industry, Biotech Private Selective collaboration 100’s of published datasets
- 6. NIH funded STTR collaboration Some collaborations outside also 1R41AI088893-01 2R42AI088893-02 Developing molecules for TB Using computational data mining New technologies for TB drug discovery
- 7. From Desktop to Mobile apps – making data accessible Clark et al., submitted 2014 Predict targets http://goo.gl/vPOKS http://goo.gl/iDJFR
- 8. Drug discovery is repetitive and there are 1000s of diseases Drug discovery is high risk Do we need robots or just smarter programs that discover the ideas we test?
- 9. 24 groups in this project use a single Participants from India, Russia, South Africa, Europe, USA
- 10. TB Drug Accelerator Another example of a big TB collaboration 7 Big Pharma and 4 academic institutes will open up targeted sections of their compound libraries and share data with each other. • Abbott • AstraZeneca • Bayer • Eli Lilly • GlaxoSmithKline • Merck • Sanofi • Infectious Disease Research Institute (IDRI) • NIH National Institute of Allergy and Infectious Diseases • Texas A&M University • Weill Cornell Medical College
- 11. The Big Picture • This did not happen overnight – 10 years to get here! • Collaboration and selective secure sharing is key – move ideas and data – to clinical compounds • Domain expertise in drug discovery • Bring scientists together globally • Grants can accelerate / catalyze collaboration • Grants can fund further technology development • Impact how we develop therapies
Editor's Notes
- #4: CDD is 10 yrs old SaaS is not new Being on cloud, personal cloud is not new Sharing data , collaborations is not new We were first, we helped build foundation What we do next is important and depends on you
- #5: Molecules and biology e.g. PubChem Molecules and analytical data e.g. ChemSpider These are massive..primarily look ups - not private ....not CDD Standalone, little integration and lots of errors Need to use caution
- #8: CDD has lots of public data How to expose high value data How to create addition high value datasets TB molecules and targets TB in vivo mouse data We developed a mobile app yrs before any of our competitors Easy use Expose user to data CDD brand recognition Start something that can grow App becomes way to fast prototype ideas Data visualization, output